Oncolytics Biotech Stock Performance
| ONCY Stock | USD 1.27 0.05 3.79% |
Oncolytics Biotech holds a performance score of 16 on a scale of zero to a hundred. The company holds a Beta of 0.29, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oncolytics Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Oncolytics Biotech is expected to be smaller as well. Use Oncolytics Biotech daily balance of power, relative strength index, as well as the relationship between the downside variance and total risk alpha , to analyze future returns on Oncolytics Biotech.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Oncolytics Biotech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 10:95 | Dividend Date 2018-05-25 | Last Split Date 2018-05-25 |
1 | Oncolytics Biotech Inc Q1 2025 Earnings Call Highlights Strategic Advances Amid ... | 05/15/2025 |
2 | Oncolytic Virus Immunotherapy Strategic Research Business Report 2025-2030 Surge in Clinical Trials Combining Oncolytic Viruses With Checkpoint Inhibitors Expan... | 06/05/2025 |
3 | Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs | 06/11/2025 |
4 | With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology - The Globe and Mail | 06/20/2025 |
5 | Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies | 07/08/2025 |
6 | Oncolytics Biotech Trading Up 24.1 percent Whats Next | 07/09/2025 |
7 | Oncolytics Biotech to Host Key Opinion Leader Discussion Focusi | 07/10/2025 |
8 | Oncolytics Biotech Stock Price Up 24.1 percent Heres What Happened | 07/11/2025 |
9 | Oncolytics Biotech Presents Aggregated Translational Data Provi | 07/16/2025 |
| Begin Period Cash Flow | 34.9 M | |
| Total Cashflows From Investing Activities | -239 K |
Oncolytics | Build AI portfolio with Oncolytics Stock |
Oncolytics Biotech Relative Risk vs. Return Landscape
If you would invest 57.00 in Oncolytics Biotech on April 20, 2025 and sell it today you would earn a total of 70.00 from holding Oncolytics Biotech or generate 122.81% return on investment over 90 days. Oncolytics Biotech is currently generating 1.5649% in daily expected returns and assumes 7.6755% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Oncolytics, and 69% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncolytics Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncolytics Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncolytics Biotech, and traders can use it to determine the average amount a Oncolytics Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2039
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ONCY | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.68 actual daily | 68 68% of assets are less volatile |
Expected Return
| 1.56 actual daily | 31 69% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 16 84% of assets perform better |
Based on monthly moving average Oncolytics Biotech is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncolytics Biotech by adding it to a well-diversified portfolio.
Oncolytics Biotech Fundamentals Growth
Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.
| Return On Equity | -2.14 | ||||
| Return On Asset | -0.76 | ||||
| Current Valuation | 111.62 M | ||||
| Shares Outstanding | 96.6 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 25.86 X | ||||
| EBITDA | (34.88 M) | ||||
| Net Income | (31.71 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.06 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.42 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (26.97 M) | ||||
| Earnings Per Share | (0.29) X | ||||
| Market Capitalization | 122.68 M | ||||
| Total Asset | 20.19 M | ||||
| Retained Earnings | (477.71 M) | ||||
| Working Capital | 12.19 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
About Oncolytics Biotech Performance
Evaluating Oncolytics Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Oncolytics Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncolytics Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.57) | (1.65) | |
| Return On Capital Employed | (2.59) | (2.46) | |
| Return On Assets | (1.57) | (1.65) | |
| Return On Equity | (5.30) | (5.04) |
Things to note about Oncolytics Biotech performance evaluation
Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncolytics Biotech is way too risky over 90 days horizon | |
| Oncolytics Biotech may become a speculative penny stock | |
| Oncolytics Biotech appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (31.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (26.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Oncolytics Biotech Presents Aggregated Translational Data Provi |
- Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.